The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LFCR | +28.76% | -32.4% | -7.53% | -47% |
| S&P | +15.06% | +95.03% | +14.29% | +934% |
Lifecore Biomedical, Inc. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. It operates through the following segments: Lifecore, Curation Foods, and Others. The Lifecore segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans. The Curation Foods segment includes activities to market and pack specialty packaged whole and fresh-cut fruit and vegetables. The Other segment consists of corporate general and administrative expenses, non-Curation Foods and non-Lifecore interest income, and income tax expenses. The company was founded by Ray Stewart on October 31, 1986 and is headquartered in Santa Maria, CA.
The company failed to meet earnings expectations, causing a sharp sell-off.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $36.44M | -3.8% |
| Gross Profit | $13.98M | -19.0% |
| Gross Margin | 38.37% | -7.2% |
| Market Cap | $250.66M | 40.5% |
| Market Cap / Employee | $0.62M | 0.0% |
| Employees | 406 | -22.5% |
| Net Income | -$1.15M | 83.8% |
| EBITDA | $4.81M | 12.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $8.27M | -2.3% |
| Accounts Receivable | $43.67M | 40.2% |
| Inventory | 32.3 | -19.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $128.34M | 2.3% |
| Short Term Debt | $3.82M | -22.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -15.09% | -18.6% |
| Return On Invested Capital | -13.63% | -2.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $3.25M | -47.0% |
| Operating Free Cash Flow | $5.35M | -39.0% |
| Metric | Q2 2024 | Q3 2024 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Earnings | 24.23 | 100.67 | - | ||
| Price to Book | 11.83 | -58.14 | 13.98 | 112.46 | 612.92% |
| Price to Sales | 1.44 | 1.92 | 1.59 | 1.93 | 44.18% |
| Price to Tangible Book Value | -19.79 | -10.40 | -82.05 | -15.81 | -40.06% |
| Enterprise Value to EBITDA | -39.52 | 853.52 | -1741.04 | 87.02 | 10.76% |
| Return on Equity | 17.3% | -29.6% | -83.6% | -76.4% | -464.38% |
| Total Debt | $136.86M | $131.34M | $130.34M | $132.17M | 1.39% |
LNDC earnings call for the period ending August 29, 2021.
LNDC earnings call for the period ending May 30, 2021.
LNDC earnings call for the period ending February 28, 2021.
LNDC earnings call for the period ending August 30, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
